27-JAN-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3879 322 188 90 26 4 02/06/2019 470 182
Screened at PD     1401 157 106 52 15 3      
Pre-Screened prior to PD     2460 147 71 31 9 1      
Treatment-naive     18 18 11 7 2 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     522 26 14 6 2 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2078 325 144 72 22 4      
Screened at PD     1173 182 107 53 15 4      
Pre-Screened prior to PD     831 121 25 11 5 0      
Treatment-naive     18 18 11 7 2 0      
After PD on a Lung_MAP Sub-Study     56 4 1 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     285 285 122 59 16 4      
S1900G     34 7 3 2 1 0      
S1900J     15 7 3 1 0 0      
S1900K     34 26 16 10 5 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     577 82 63 37 12 3      
Initial sub-study registrations     565 82 63 37 12 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 55 55 49 28 7 3 05/22/2025 352 114
Docetaxel plus Ramucirumab Y   29 29 26 14 4 2      
Cemiplimab plus Docetaxel and Ramucirumab Y   26 26 23 14 3 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 24 7 3 2 1 0 05/05/2023 340 109
Capmatinib + Osimertinib + Ramucirumab Y   14 6 3 2 1 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 0 0 0 11/19/2024 240 79
Amivantamab Hyaluronidase Y   3 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 21 18 10 7 4 0 08/08/2024 268 89
Tepotinib + Ramucirumab Y   13 11 5 4 3 0      
Tepotinib Y   8 7 5 3 1 0